Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

12 trials with published results (67%)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

72%

13 trials in Phase 3/4

Results Transparency

86%

12 of 14 completed with results

Key Signals

12 with results100% success

Data Visualizations

Phase Distribution

16Total
P 2 (3)
P 3 (12)
P 4 (1)

Trial Status

Completed14
Withdrawn2
Active Not Recruiting1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 14 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT05148702Phase 3Active Not RecruitingPrimary

EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.

NCT05905055Phase 3Completed

P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales

NCT05733104RecruitingPrimary

A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea

NCT03329092Phase 3CompletedPrimary

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

NCT04927312Phase 3CompletedPrimary

Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection

NCT03217136Phase 2CompletedPrimary

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

NCT01265784Phase 2CompletedPrimary

Study to Compare TP-434 and Ertapenem in Community-acquired Complicated Intra-abdominal Infections

NCT03293485Phase 3CompletedPrimary

Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)

NCT01445678Phase 3CompletedPrimary

Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections

NCT01147640Phase 2CompletedPrimary

Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

NCT02739997Phase 3Completed

Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)

NCT01644643Phase 3Completed

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01499290Phase 3CompletedPrimary

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

NCT01726023Phase 3CompletedPrimary

Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections

NCT00157898Phase 4CompletedPrimary

A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)

NCT01602874Phase 3Withdrawn

Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia

NCT00929643CompletedPrimary

Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections

NCT00914888Phase 3Withdrawn

Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia

Showing all 18 trials

Research Network

Activity Timeline